Advanced Search

Home > News > Call for Papers for Prevention & Control of Coronavirus Disease (COVID-19)

Time: February 1, 2021

Journal:  Exploratory Research and Hypothesis in Medicine

Special Issue: Prevention & Control of Coronavirus Disease (COVID-19)

Guest Editors: Dr. Zhen-peng Huang, Dr. Zhaohui Bai 

Status: Open

Submission deadline: October 31, 2021

Publication date: An article will be published online as soon as it is accepted.

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), is now a global pandemic, but a huge knowledge gap remains about the effects of this novel virus on the human body. Given the current global public health threat, there is an urgent need for fast diagnosis, preventive, and therapeutic measures for COVID-19.

For this special issue, we invite front-line researchers and scientists to submit high-quality scientific manuscripts regarding COVID-19. Potential topics include, but are not limited to:

  • COVID-19 complications  
  • COVID-19 diagnosis  
  • Genetic analysis  
  • Medical imaging  
  • Clinical features and symptoms  
  • Epidemiological investigation  
  • Outbreak control and risk assessment 
  • Transmission mechanism and prevention  
  • Community health and telemedicine
  • COVID-19 and related organs or systems injure

Authors should refer to the Instructions for Authors in preparing the manuscript and kindlysubmit it through the Online Submission System directly.

Priority will be given with the same high standards of peer review and publication process for these articles. To help fight the epidemic, authors publishing papers regarding COVID-19 will not be charged any fees and all publications will open free access to all readers. We guarantee that all accepted papers related to COVID-19 will be highlighted in a special
section on our website.

Guest Editors’ Profiles:


Zhen-peng Huang, M.D., D.M.

Dr. Zhen-peng Huang is an Associate Professor of the Affiliated Cancer Hospital & Institute of Guangzhou Medical University, China. He graduated from Wuhan University in 2017. Dr. Huang specializes in basic and clinical studies of functional gastrointestinal disorders (FGIDs). His research activity has been reported in papers published in peer-reviewed international journals as well as in presentations at international and national conferences. He is a fellow of the American Association for the Study of Liver Diseases (AASLD) and a member of the Rome Foundation. Also, he has won the AASLD-CFHPC Hepatology Connect Conference Award (March 2019) and the 3rd Annual Rome Foundation Mentorship Program Award (May 2019). He serves on the editorial boards of several scientific journals and serves as a reviewer for multiple prestigious journals.

Zhaohui Bai, M.D., D.M.

Zhaohui Bai works at the School of Life Sciences and Biopharmaceutis, Shenyang Pharmaceutical University and the Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, P.R. China. He specializes in hepatology, gastroenterology, and clinical pharmacy. Dr. Bai has many publications in peer-reviewed journals. Liver cirrhosis is a serious disease that cannot be cured. The economic burden of hospitalizations due to liver cirrhosis has increased in recent years worldwide. Dr. Bai research focuses on liver cirrhosis and its complications. Specific examples included the prevention and treatment of hepatic encephalopathy1,2, gastrointestinal bleeding3-10, ascites11,12, liver failure13-15, portal hypertension and portal vein thrombosise16-18, Budd-Chiari syndrome19, and spontaneous bacterial peritonitis20.

Online submission system: https://www.publinexh.com/

Article processing charge: None

Instructions for authors: Please state in a cover letter that the manuscript is being submitted for inclusion in the special issue ‘Prevention & Control of Coronavirus Disease (COVID-19)’, and follow the usual ERHM instructions. Please refer to:https://www.xiahepublishing.com/journal/erhm/instruction

For any inquiries, please contact the journal by e-mail: [email protected]


[1] Bai Z, Bernardi M, Yoshida E. M, et al. Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis. Aging (Albany NY). 2019 Oct 8;11(19):8502-8525.
[2] Bai Z, Guo X, Tacke F, et al. Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization. Therapeutic Advances in Gastroenterology. 2019 Oct 7;12:1756284819881302.
[3] Bai Z#, Li B#, Lin S#, et al. Development and Validation of CAGIB Score for Evaluating the Prognosis of Cirrhosis with Acute Gastrointestinal Bleeding: a Retrospective Multicenter study. Advances in Therapy. 2019 Nov;36(11):3211-3220.
[4] An Y#, Bai Z#, Xu X#, et al. No benefit of hemostatic drugs on acute upper gastrointestinal bleeding in cirrhosis. BioMed Research International. In Press.
[5] Bai Z, Massimo P, Guo X, et al. Incidence and mortality of renal dysfunction in cirrhotic patients with acute gastrointestinal bleeding: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2019 Dec;13(12):1181-1188.
[6] Bai Z#, Guo X#, Li H, et al. Should red blood cell transfusion be immediately given to a cirrhotic patient with active upper gastrointestinal bleeding? AME Med J 2018;3:83.
[7] Yi F, Bai Z, Li Y, Xu X, Guo X, Qi X. A good response to glucocorticoid for Henoch-Sch?nlein purpura with abdominal pain and gastrointestinal bleeding in an adult: A CARE case report. Medicine (Baltimore). 2020 Jan;99(1):e18602.
[8] Bai Z#, Guo X#, Shao X, et al. Successful treatment of repeated hematemesis secondary to post-sclerotherapy esophageal ulcer in a cirrhotic patient: A case report. Drug Discov Ther. 2018;12(5):309-314.
[9] Li Y, Han B, Li H, et al. Effect of Admission Time on the Outcomes of Liver Cirrhosis with Acute Upper Gastrointestinal Bleeding: Regular Hours versus Off-Hours Admission. Can J Gastroenterol Hepatol. 2018 Nov 29;2018:3541365.
[10] Li Y, Guo X, Bai Z, et al. Banana may be forbidden after endoscopic variceal ligation: a case report. Transl Gastroenterol Hepatol. 2019 Feb 20;4:13.
[11] Bai Z#, An Y#, Guo X#, et al. Role of terlipressin in cirrhotic patients with ascites and without hepatorenal syndrome: A systematic review of current evidence. Canadian Journal of Gastroenterology and Hepatology. In Press.
[12] Bai Z, Li H, Guo X, Qi X. Use of Terlipressin in Cirrhosis With Ascites: A Questionnaire Survey in China. Journal of Clinical and Experimental Hepatology. doi:10.1016/j.jceh.2019.11.010.
[13] Bai Z#, Li H#, Zheng K#, et al. A good response to glucocorticoid for sub-acute liver failure: a case report. Transl Gastroenterol Hepatol. 2018 May 3;3:25.
[14] Bai Z#, Li H#, Guo X#, et al. Successful treatment of acute-on-chronic liver failure and hemolytic anemia with hepato-protective drugs in combination with intravenous ozone without steroids: A case report. Intractable Rare Dis Res. 2018 Aug;7(3):204-208.
[15] Xu X, Bai Z, Zhao Q, et al. Successful Pharmacotherapy for Multiple Acute Decompensation Events in a Cirrhotic Patient with Acute-on-chronic Liver Failure: A Case Report. J Transl Int Med. 2018 Dec 31;6(4):189-193.
[16] Lin H#, Bai Z#, Guo X#, et al. Association between non-alcoholic fatty liver disease and portal vein thrombosis: A systematic review and meta-analysis. European Journal of Gastroenterology & Hepatology. In Press.
[17] Xu X, Guo X, De Stefano V, et al. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Hepatol Int. 2019 Jul;13(4):468-481.
[18] Zheng K, Guo X, Feng J, et al. Gastrointestinal Bleeding due to Pancreatic Disease-Related Portal Hypertension. Gastroenterol Res Pract. 2020 Mar 27;2020:3825186.
[19] Li Y, De Stefano V, Li H, et al. Epidemiology of Budd-Chiari syndrome: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2019 Aug;43(4):468-474.
[20] Han D, Wang R, Yu Y, et al. Xuebijing Injection Combined with Antibiotics for the Treatment of Spontaneous Bacterial Peritonitis in Liver Cirrhosis: A Meta-Analysis. Evid Based Complement Alternat Med. 2018 Mar 19;2018:2989846.
Back to Top